NCT04018599 - Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS | Biotech Hunter

Enrollment

216

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

March 17, 2020

Study Completion Date

March 17, 2020

Conditions

Rheumatoid ArthritisPolyarticular Juvenile Idiopathic ArthritisPsoriatic ArthritisAnkylosing SpondylitisCrohn DiseaseUlcerative ColitisPlaque PsoriasisPediatric Plaque PsoriasisPediatric Crohns DiseaseHidradenitis SuppurativaNon-infectious Uveitis

Interventions

DRUG

40 mg MSB11022

Single dose, as a solution, administered subcutaneously, using an auto-injector.

DRUG

40 mg MSB11022

Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.

Trial Locations (2)

66219

PRA Health Sciences (PRA) - Early Development Services (EDS), Lenexa

84124

PRA-EDS, Salt Lake City